Low-hemoglobin Polycythemia Vera: Diagnostic Criteria and Clinico-pathological Characterization

Blood is a living river that carries oxygen to every corner of the body, and its volume is carefully regulated by the body's internal thermostat. When this system malfunctions, the bone marrow can begin to produce too many red blood cells, a condition known as polycythemia vera. This excess thickens the blood, turning it sluggish and increasing the risk of dangerous clots that can block vital vessels. For decades, doctors have relied on two simple numbers to spot this disease: the concentration of hemoglobin, the protein that carries oxygen, and the hematocrit, which measures the percentage of blood volume made up of red cells. If these numbers climb above a certain line, the diagnosis is clear. However, a significant group of patients falls into a gray area. They carry the specific genetic mutation that causes the disease and have a true excess of red cells, yet their hemoglobin and hematocrit levels remain stubbornly below the official cutoff. These patients often slip through the cracks, misdiagnosed with a different, less aggressive blood disorder, leaving them without the specific treatment needed to prevent life-threatening clots.

A team of researchers at several hospitals in Barcelona set out to solve this diagnostic puzzle by looking beyond the standard blood counts. They focused on a group of patients who possessed the genetic signature of polycythemia vera but had hemoglobin levels that were too low to trigger a formal diagnosis under current rules. The researchers called this group "low-hemoglobin polycythemia vera." To understand what was truly happening inside these patients, they performed a specialized test to measure the actual total volume of red cells in the body, a measurement that is rarely done in routine practice because it requires complex isotopic techniques. By comparing these patients against others with clear-cut cases of the disease and those with a related condition called essential thrombocythemia, the team mapped the biological landscape of this hidden group. They found that these patients were not merely borderline cases; they were biologically closer to the full-blown disease than to the milder condition. Their blood clotted more easily, their spleens were more often enlarged, and their genetic profiles showed a higher risk of aggressive disease, placing them firmly on the spectrum of polycythemia vera rather than the milder alternative.

The study, which analyzed nearly three hundred patients, revealed that the current reliance on hemoglobin and hematocrit levels is insufficient, particularly for women. The researchers discovered that the number of red blood cells circulating in the veins is a far more accurate indicator of the true disease state than the concentration of hemoglobin. In women, counting the actual number of red cells provided a much sharper picture of who had the dangerous excess of blood volume. The team identified specific thresholds for this count: a level above 5.6 trillion cells per liter for women and above 5.9 trillion for men. These numbers acted as a reliable filter, correctly identifying patients with the true disease who would otherwise have been missed. The findings suggest that the medical community needs to update its diagnostic toolkit. By incorporating the simple red blood cell count alongside genetic testing and other markers, doctors could catch these hidden cases earlier. This shift would ensure that patients receive the correct management to control their blood thickness and prevent the severe complications that arise when the disease goes unrecognized.

The researchers also examined the genetic makeup of the patients, looking for specific mutations that might signal a higher risk. They found a clear gradient in the severity of the genetic profile, moving from the milder condition to the low-hemoglobin group and finally to the classic disease. The patients in the middle, the low-hemoglobin group, carried genetic markers that were more similar to the severe form of the disease than to the milder one. This molecular evidence reinforced the idea that these patients should be treated as having polycythemia vera. Furthermore, the study challenged the heavy reliance on bone marrow biopsies, a procedure where a small sample of the marrow is taken to look for signs of the disease. The researchers found that the appearance of the bone marrow did not always match the clinical reality; many patients who clearly had the disease showed normal or ambiguous results in their marrow samples. This suggests that the diagnosis should rely more on the combination of blood counts, genetic markers, and the actual volume of red cells, rather than on the sometimes inconclusive look of the marrow tissue.

Ultimately, the work highlights a gap in how blood disorders are currently classified and treated. The study demonstrates that a significant number of patients are living with a dangerous form of blood disease that goes undetected because their numbers do not cross an arbitrary line. By recognizing that the total number of red cells is a more faithful witness to the disease than the concentration of hemoglobin, the medical field can close this diagnostic gap. The authors propose that future guidelines should include these red cell counts as a standard part of the diagnostic criteria. This change would not only improve accuracy but also align treatment with the true biological risk of the patient, ensuring that those who need protection from clots receive it, regardless of whether their hemoglobin levels have reached the traditional threshold. The research confirms that the disease exists on a continuum, and the tools used to measure it must be sensitive enough to see the whole picture, not just the parts that fit a rigid definition.